SPSymbiotec Pharmalab544889Quarterly results

Symbiotec Pharmalab Q2 FY27: revenue up 43% to Rs. 280 crore, PAT up 169% to Rs. 52 crore

Q2 FY27 revenue up 43% to Rs. 280 crore, profit after tax up 169% to Rs. 52 crore.

By ScoutQuest · Thu 5 Nov 2026, 8:22 PM IST · 1 min read

Q2 FY27 consolidated revenue

Rs. 280 crore against Rs. 196 crore a year earlier, up 43%

Q2 FY27 profit after tax

Rs. 52 crore versus Rs. 19 crore, up 169%

Gross capex as on 30 September 2026

Rs. 1,509 crore as on 30 September 2026

Period

Q2 & H1 FY27, ended September 2026

Positioning

The company presents itself as a builder of leadership in steroids and hormones since 2004, now leveraging fermentation to expand into complex injectables and biotech CDMO.

📈 Q2 FY27 consolidated revenue was Rs. 280 crore against Rs. 196 crore a year earlier, up 43%, with reported EBITDA of Rs. 92 crore (up 82%) and profit after tax of Rs. 52 crore versus Rs. 19 crore, up 169%; for H1 FY27 revenue was Rs. 498 crore and profit after tax Rs. 66 crore.

📈 Gross margin rose to 71.6% in Q2 FY27 from 64.1%, lifting PAT margin to 18.5% from 9.8%; the company notes EBITDA carries a one-time Rs. 3 crore IPO listing expense, while Q2 new-business operating expenses of Rs. 31 crore (versus Rs. 8 crore) and new-business depreciation of Rs. 12 crore (versus Rs. 1 crore) kept H1 FY27 EBITDA margin almost flat at 27.3% against 27.2%.

🏭 Gross capex was Rs. 1,509 crore as on 30 September 2026 and is estimated at Rs. 1,672 crore by end FY27; the presentation shows 39% of it currently generating revenue and 61% sitting in new projects yet to earn, alongside net debt of about Rs. 314 crore as on 30 September 2026.

🌍 Management states API revenue grew 11% year on year in H1 FY27 on volume growth and a favourable product mix, and that a US licensing agreement for two DCV products was partly recognised in Q2 FY27; it says a 10-year take-or-pay CDMO agreement with a Europe-based alternative-protein company is at an advanced stage and that injectables and CDMO can eventually reach a size comparable to the API business.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev